Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and hematologic cancer risk among older adults with type 2 diabetes.

6592 Background: Recent preclinical and clinical evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RA) may reduce cancer risk through inflammation modulation. However, comparative effectiveness research evaluating hematologic malignancy risks of GLP-1 RAs remain limited in real-world populations. Methods: Using 15% random samples of Medicare Part D beneficiaries from 2013 to 2022, we identified older adults with type 2 diabetes who initiated GLP-1 RA or DPP-4i. The primary outcomes included myelodysplastic syndromes (MDS), lymphoma, and leukemia. We performed 1:1 propensity score matching for confounding control. We estimated the hazard ratios (HR) and 95% confidence intervals (CI) with Cox proportional hazard model. We examined the heterogeneity in treatment effects by pre-specified patient demographic and baseline factors. Subgroup analyses were conducted for: a) age (≥75 vs.